Literature DB >> 15471373

T1 relaxation maps allow differentiation between pathologic tissue subsets in relapsing-remitting and secondary progressive multiple sclerosis.

A Castriota-Scanderbeg1, F Fasano, M Filippi, C Caltagirone.   

Abstract

In an attempt to clarify whether T1 relaxation time mapping may assist in characterizing the pathological brain tissue substrate of multiple sclerosis (MS), we compared the T1 relaxation times of lesions, areas of normal-appearing white matter (NAWM) located proximal to lesions, and areas of NAWM located distant from lesions in 12 patients with the relapsing-remitting and 12 with the secondary progressive (SP) subtype of disease. Nine healthy volunteers served as controls. Calculated mean T1 values were averaged across all patients within each clinical group, and comparisons were made by means of the Mann-Whitney U-test. Significant differences were found between all investigated brain regions within each clinical subgroup. Significant differences were also detected for each investigated brain region among clinical subgroups. While T1 values of NAWM were significantly higher in patients with SP disease than in normal white matter (NWM) of controls, no differences were detected when corresponding brain areas of patients with RR MS were compared with NWM of controls. T1 maps identify areas of the brain that are damaged to a different extent in patients with MS, and may be of help in monitoring disease progression.

Entities:  

Mesh:

Year:  2004        PMID: 15471373     DOI: 10.1191/1352458504ms1073oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  8 in total

1.  Voxel-based analysis of quantitative T1 maps demonstrates that multiple sclerosis acts throughout the normal-appearing white matter.

Authors:  H Vrenken; S A R B Rombouts; P J W Pouwels; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2006-04       Impact factor: 3.825

Review 2.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 3.  Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.

Authors:  Tim Sinnecker; Cristina Granziera; Jens Wuerfel; Regina Schlaeger
Journal:  Curr Treat Options Neurol       Date:  2018-04-20       Impact factor: 3.598

4.  Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis.

Authors:  H Vrenken; J J G Geurts; D L Knol; C H Polman; J A Castelijns; P J W Pouwels; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2006-10       Impact factor: 3.825

5.  Statistical estimation of T1 relaxation times using conventional magnetic resonance imaging.

Authors:  Amanda F Mejia; Elizabeth M Sweeney; Blake Dewey; Govind Nair; Pascal Sati; Colin Shea; Daniel S Reich; Russell T Shinohara
Journal:  Neuroimage       Date:  2015-12-28       Impact factor: 6.556

6.  Fast whole-brain three-dimensional macromolecular proton fraction mapping in multiple sclerosis.

Authors:  Vasily L Yarnykh; James D Bowen; Alexey Samsonov; Pavle Repovic; Angeli Mayadev; Peiqing Qian; Beena Gangadharan; Bart P Keogh; Kenneth R Maravilla; Lily K Jung Henson
Journal:  Radiology       Date:  2014-09-10       Impact factor: 11.105

7.  T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.

Authors:  Christian Thaler; Tobias Faizy; Jan Sedlacik; Brigitte Holst; Jan-Patrick Stellmann; Kim Lea Young; Christoph Heesen; Jens Fiehler; Susanne Siemonsen
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

8.  MP2RAGE provides new clinically-compatible correlates of mild cognitive deficits in relapsing-remitting multiple sclerosis.

Authors:  Samanta Simioni; Fabio Amarù; Guillaume Bonnier; Tobias Kober; David Rotzinger; Renaud Du Pasquier; Myriam Schluep; Reto Meuli; Andrea Sbarbati; Jean-Philippe Thiran; Gunnar Krueger; Cristina Granziera
Journal:  J Neurol       Date:  2014-06-10       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.